RusnanoMedInvest
Venture capital company

RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.

About us

 

We are investing
in the development of innovative drugs

We are interested in cooperation with the authors of new promising ideas in the field of pharmaceuticals and medical equipment.

Portfolio

RMI - international cooperation

We implement an agreement between large and reputable companies in the United States and Russia

Rusnano and Domain have made an agreement on joint investments in pharmaceuticals and medical development for innovation.

About agreement

RusnanoMedInvest
Venture capital company

RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.

Our history

RusnanoMedInvest (RMI) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology

RMI venture fund is currently managed by RMI Partners, a venture capital company focused on breakthrough developments of pharmaceutical products and technologies.  

RMI was created in March 2012. Initial funding - $380 million. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government. 

The RusnanoMedInvest fund seeks, in addition to securing differentiated and sustainable returns to its investment portfolio, to promote the following social and developmental objectives in Russia

  • localization of innovative life sciences and pharmaceutical technology in Russia;
  • creation and accumulation of  Russian-originated world-class expertise in the field of venture capital financing in Life Sciences;
  • stimulating the interest of investors and potential investors in the financing of Russian life sciences ideas, concepts and technologies.

Read more

All Partners

All Portfolio

MEDIA CENTER

  • Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH

    Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH

    Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that they have entered into a definitive agreement under which  Allergan  will acquire Tobira for an upfront payment of  $28.35  per share, in cash, and up to  $49.84  per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to  $1.695 billion . The Boards of Directors of both companies have unanimously approved the transaction.

All news